Diethyltoluamide

Summary

Diethyltoluamide (CHEMBL1453317) is an approved small-molecule insect repellent (ATC P03BX01); indicated across 1 condition including parasitic infectious disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: P03BX01
• Indications: 1 condition
• Chemistry: 191.27 Da · C12H17NO

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1453317
Name	Diethyltoluamide
Type	Small molecule
Max phase	3
FDA approved	yes
PubChem CID	4284
ChEBI	CHEBI:7071
ATC	P03BX01
Molecular formula	C12H17NO
Molecular weight	191.27
InChIKey	MMOXZBCLCQITDF-UHFFFAOYSA-N

SMILES: CCN(CC)C(=O)C1=CC=CC(=C1)C

IUPAC name: N,N-diethyl-3-methylbenzamide

ChEBI definition: A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of m-toluic acid with the nitrogen of diethylamine. First developed by the U.S. Army in 1946 for use by military personnel in insect-infested areas, it is the most widely used insect repellent worldwide.

Pharmacological roles (ChEBI): insect repellent.

Other ChEBI roles (chemical / environmental): environmental contaminant, xenobiotic.

Also known as: Deet, Deet n, n-diethyl-meta-toluamide, Diethyl toluamide, Diethyltoluamide, Diethyltoluamidum, Dietiltoluamida, ENT-20218, ENT-22542, N, NSC-33840, Oristar deet

Patent coverage: 7,427 distinct patent families (21,167 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 20,770 (98%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Ferritin light chain, 15-hydroxyprostaglandin dehydrogenase [NAD(+)].

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 4 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
TDP1	5.8	Potency	1585	nM	CHEMBL_ACT_3933754

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
parasitic infectious disease	4	MONDO:0005135	EFO:0001067

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).